Skip to content

The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks

The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07679321
Enrollment
256
Registered
2026-07-01
Start date
2024-12-01
Completion date
2027-12-30
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety/Depression and Asthma

Brief summary

The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety/depression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions. Participants will: Complete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety/depression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up

Interventions

No intervention measures

Sponsors

Xiangya Hospital of Central South University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria. * Male or female patients aged 14 years or older. * Complete clinical data available. * Newly diagnosed asthma or stable asthma. * Receiving asthma controller medication.

Exclusion criteria

* History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery. * Incomplete medical records. * Cognitive impairment or inability to complete psychological scale assessments. * Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia. * Current use of antidepressant or anti-anxiety medications. * Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
Acute asthma attack1 yearNumber of acute asthma attacks in patients during follow-up period

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026